415
Participants
Start Date
September 30, 2008
Primary Completion Date
December 31, 2011
Study Completion Date
January 31, 2012
MORAb-003 (farletuzumab)
Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
0.9% Saline
Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
Paclitaxel
Prince of Wales Hospital, Randwick
Westmead Hospital, Westmead
The Royal Women's Hospital, Parkville
Mercy Hospital for Women, Heidelburg
Monash Medical Centre, East Bentleigh
Royal Brisbane & Women's Hospital, Herston
The Burnside War Memorial Hospital, Inc., Toorak Gardens
St. John of God Hospital, Subiaco
Sir Charles Gairdner Hospital, Nedlands
St. Luke's Roosevelt Hospital Center, New York
Memorial Sloan-Kettering Cancer Center, New York
Arena Oncology Associates, PC, Lake Success
Schwartz Gynecologic Oncology, PLLC, Brightwaters
Magee-Women's Hospital of UPMC, Pittsburgh
Abington Memorial Hospital, Abington
Johns Hopkins Hospital, Baltimore
Weinberg Cancer Institute at Franklin Square, Baltimore
Northern Virginia Pelvic Surgery Associates, Annandale
Piedmont Hematology Oncology Associates, PA, Winston-Salem
Hospital Universitario 12 de Octubre, Madrid
Fundacion Hospital Alcorcon, Alcorcón
Medical University of South Carolina, Charleston
Memorial Health University Medical Center, Savannah
Florida Hospital Cancer Institute, Orlando
Innovative Medical Research of South Florida, Inc., Miami
Jupiter Medical Center, Jupiter
Sarasota Memorial Hospital, Sarasota
Southern Cancer Center, Mobile
Cleveland Clinic, Cleveland
Signal Point Clinical Research Center, Middletown
St. Vincent Gynecologic Oncology, Indianapolis
Henry Ford Health System, Detroit
Central DuPage Hospital, Winfield
Hematology and Oncology Specialists, LLC, Metairie
Cancer Care Associates, Tulsa
Scott & White Memorial Hospital and Clinic, Temple
South Texas Oncology & Hematology PA, San Antonio
International Beneficence Clinical Research, LLC, Harlingen
Utah Cancer Specialists, Salt Lake City
St. Joseph's Hospital and Medical Center, Phoenix
USC/Norris Comprehensive Cancer Center, Los Angeles
Moores UC San Diego Cancer Center, La Jolla
Monterey Bay Oncology, Monterey
California Cancer Care, Inc., Greenbrae
Morristown Memorial Hospital, Morristown
AZ Greninge Hospital, Kortrijk
University Hospitals Leuven, Leuven
CHU de Liege, Liège
Tom Baker Cancer Centre, Calgary
BC Cancer Agency, Kelowna
Juravinski Cancer Centre, Hamilton
Sunnybrook Health Sciences Centre, Toronto
UMCG, Groningen
University Hospital Maastricht, Maastricht
UMC Utrecht, Utrecht
Hospital Universitario Son Dureta, Palma de Mallorca
Hospital de Son Llatzer, Palma de Mallorca
Hospital Clinic I Provincial, Barcelona
Hospital de Mataro, Mataró
Corporacio Sanitaria Parc Taulis, Sabadell
Consorci Sanitari de Terrassa, Terrassa
Lead Sponsor
Morphotek
INDUSTRY